RT Journal Article
SR Electronic
T1 Impairment of T cells’ antiviral and anti-inflammation immunities dominates the death from COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21256093
DO 10.1101/2021.04.26.21256093
A1 Zhang, Luhao
A1 Li, Rong
A1 Song, Gang
A1 Scholes, Gregory D.
A1 She, Zhen-Su
YR 2021
UL http://medrxiv.org/content/early/2021/04/29/2021.04.26.21256093.abstract
AB Clarifying key factors dominating the immune heterogeneity from non-survivors to survivors is crucial for therapeutics and vaccine developments against COVID-19. The main difficulty is to quantitatively analyze the multi-level clinical data of viral dynamics, immune response, and tissue damages. Here, we adopt top-down modeling to quantify key functional aspects and their dynamical interplays in the virus-immune system battle, yielding an accurate description of real-time clinical data involving hundreds of patients for the first time. The quantification of antiviral responses demonstrates T cells’ dominant role in the virus clearance relative to antibodies, especially for mild patients (96.5%). Moreover, the anti-inflammatory responses, namely cytokine inhibition rate and tissue repair rate also have positive correlations with T cell number, and are significantly suppressed in non-survivors. Simulations show that impaired immune functions of T cells leads to greater inflammation (thus dominates the death), explaining the monotonous increase of COVID-19 mortality with age and higher mortality for males. We conclude that T cells play the role of crucial immunity that saves the death from COVID-19, which points out a new direction to advance current prevention and treatment by incorporating the vaccines, drugs and health care activities that aim to improve T cells’ number and functions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialWe used published data for study. We do not perform our own clinical trialFunding StatementThe research is funded by the W.M. Keck Foundation through award no. 1005586. The authors acknowledge Prof. Kelvin To for sharing data, and Xiaoquan Wang, Guanghui She for discussion.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a theoretical work anaylizing clincal data that published previously so the ethical didelines are followed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the codes to produce figures in our manuscript can be accessed using the following link https://github.com/luhaozhang/covid19.git